Search results
Showing 2901 to 2950 of 4138 results for patient
Awaiting development Reference number: GID-TA11516 Expected publication date: 06 May 2027
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Awaiting development Reference number: GID-TA11383 Expected publication date: TBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941
Awaiting development Reference number: GID-TA11481 Expected publication date: TBC
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]
Awaiting development Reference number: GID-TA11417 Expected publication date: TBC
Awaiting development Reference number: GID-TA11549 Expected publication date: TBC
Awaiting development Reference number: GID-TA11581 Expected publication date: TBC
Awaiting development Reference number: GID-TA11594 Expected publication date: TBC
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
Awaiting development Reference number: GID-TA11596 Expected publication date: TBC
Awaiting development Reference number: GID-TA11825 Expected publication date: TBC
Awaiting development Reference number: GID-TA11558 Expected publication date: TBC
Awaiting development Reference number: GID-TA11880 Expected publication date: TBC
Awaiting development Reference number: GID-TA11882 Expected publication date: TBC
Obinutuzumab for treating serologically active extra-renal lupus [TSID12285]
Awaiting development Reference number: GID-TA11886 Expected publication date: TBC
Awaiting development Reference number: GID-TA11883 Expected publication date: TBC
Awaiting development Reference number: GID-TA11885 Expected publication date: TBC
Awaiting development Reference number: GID-TA11878 Expected publication date: TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Awaiting development Reference number: GID-TA11881 Expected publication date: TBC
For which people with impetigo are antiseptics as effective as antibiotics?
decision, taking local antimicrobial resistance data into account alongside patient preference, practicalities of administration,...
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
Discontinued Reference number: GID-TAG507
Myocardial infarction: medication for MI in preceding 12 months (IND125)
This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]
Awaiting development Reference number: GID-TA11741 Expected publication date: TBC
Awaiting development Reference number: GID-TA11753 Expected publication date: TBC
In development Reference number: GID-TA11229 Expected publication date: TBC
In development Reference number: GID-TA11803 Expected publication date: TBC
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]
Awaiting development Reference number: GID-TA11775 Expected publication date: TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Awaiting development Reference number: GID-TA11782 Expected publication date: TBC
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]
Awaiting development Reference number: GID-TA11744 Expected publication date: TBC
Awaiting development Reference number: GID-TA11743 Expected publication date: TBC
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]
Awaiting development Reference number: GID-TA11667 Expected publication date: TBC
Awaiting development Reference number: GID-TA11758 Expected publication date: TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]
Awaiting development Reference number: GID-TA11692 Expected publication date: TBC
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [TSID9130]
Awaiting development Reference number: GID-TA11325 Expected publication date: TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]
Awaiting development Reference number: GID-TA11755 Expected publication date: TBC
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
Awaiting development Reference number: GID-TA11534 Expected publication date: TBC
Awaiting development Reference number: GID-TA11040 Expected publication date: TBC
Awaiting development Reference number: GID-TA11161 Expected publication date: TBC
Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI
In development Reference number: GID-IPG10439 Expected publication date: TBC
Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.
Weight management: BMI recording (long term conditions) (IND320)
This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, at high risk of developing type 2 diabetes, hypertension, peripheral arterial disease, heart failure, COPD, dyslipidaemia, learning disability, obstructive sleep apnoea, schizophrenia, bipolar disorder or other psychoses who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Fertility clinics must end unproven treatments that don't help couples have babies
Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Awaiting development Reference number: GID-TA11100 Expected publication date: TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development Reference number: GID-TA11160 Expected publication date: TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development Reference number: GID-TA11300 Expected publication date: TBC
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]
Awaiting development Reference number: GID-TA10993 Expected publication date: TBC
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
Awaiting development Reference number: GID-TA11784 Expected publication date: 21 July 2027